학술논문

Mitochondrial DNA Stimulates TLR9-Dependent Neutrophil Extracellular Trap Formation in Primary Graft Dysfunction
Document Type
article
Source
American Journal of Respiratory Cell and Molecular Biology. 62(3)
Subject
Lung
Transplantation
Organ Transplantation
Rare Diseases
Genetics
Acute Respiratory Distress Syndrome
Acute Lung Injury
Animals
Bronchoalveolar Lavage Fluid
Citrullination
Cold Ischemia
DNA
Mitochondrial
Deoxyribonuclease I
Extracellular Traps
Humans
Lung Transplantation
Male
Mice
Mice
Inbred C57BL
Neutrophils
Primary Graft Dysfunction
Protein-Arginine Deiminase Type 4
Reperfusion Injury
Specific Pathogen-Free Organisms
Toll-Like Receptor 9
Warm Ischemia
primary graft dysfunction
mitochondrial DNA
neutrophil extracellular traps
TLR9
Cardiorespiratory Medicine and Haematology
Respiratory System
Language
Abstract
The immune system is designed to robustly respond to pathogenic stimuli but to be tolerant to endogenous ligands to not trigger autoimmunity. Here, we studied an endogenous damage-associated molecular pattern, mitochondrial DNA (mtDNA), during primary graft dysfunction (PGD) after lung transplantation. We hypothesized that cell-free mtDNA released during lung ischemia-reperfusion triggers neutrophil extracellular trap (NET) formation via TLR9 signaling. We found that mtDNA increases in the BAL fluid of experimental PGD (prolonged cold ischemia followed by orthotopic lung transplantation) and not in control transplants with minimal warm ischemia. The adoptive transfer of mtDNA into the minimal warm ischemia graft immediately before lung anastomosis induces NET formation and lung injury. TLR9 deficiency in neutrophils prevents mtDNA-induced NETs, and TLR9 deficiency in either the lung donor or recipient decreases NET formation and lung injury in the PGD model. Compared with human lung transplant recipients without PGD, severe PGD was associated with high levels of BAL mtDNA and NETs, with evidence of relative deficiency in DNaseI. We conclude that mtDNA released during lung ischemia-reperfusion triggers TLR9-dependent NET formation and drives lung injury. In PGD, DNaseI therapy has a potential dual benefit of neutralizing a major NET trigger (mtDNA) in addition to dismantling pathogenic NETs.